Stock offering coming up:
Total Cash (mrq): 5.72M
Total Cash Per Share (mrq): 0.57
Total Debt (mrq): 663.63K
Total Debt/Equity (mrq): 12.12
Current Ratio (mrq): 3.65
Book Value Per Share (mrq): 0.60
They just don't have enough money to start a Phase anything trial.
so the ASX to NSDQ is 15 to 1? I got 17 to one. Can't find conversion rate on their site. Where do you find this info? Have had trouble in past with other Aussie stocks.
Don't see anything?
So we are looking at a 12% dilution but won't know price until?
With this recent stock offering what does this equal as all stated in ASX not NASDAQ
Conclusion 5 → NurOwn's advantage vs. competitors looks to be its mode of administration and benign safety profile.
Brainstorm Cell Therapeutics is currently enrolling patients in a Phase 2 study (NCT02017912), with one site at the Mayo Clinic, the U.S. No. 1 ranked hospital for Neurology & Neurosurgery. A second site in this trial (there are three sites total), the Massachusetts General Hospital, is ranked No. 4 on that list. Earlier in the month, Emory University Neurologist and CNN Chief Medical Correspondent, Dr. Sanhay Gupta, wrote a brief article noting that there finally may be "Some Hope For People With ALS." We discussed this in an article posted on Seeking-Alpha last week.
We remain fans of Brainstorm Cell Therapeutics. We believe this is a stock investor should own at this level given a favorable risk / reward profile and tremendous upside for NurOwn in ALS, as well as other indications such as Autism and Multiple Sclerosis. As outlined in our Zacks report, we think the stock is worth $10 per share, which is a double from today's price.